Stimulatory effect of clebopride on human prolactin secretion.
Serum levels of prolactin (PRL), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured in normally cycling women and normal men before and after oral admiministration of 1 mg of clebopride, a derivative of procainamide used in the treatment of gastrointestinal diseases. Clebopride produced a significant increase (P < 0.001) in serum PRL to a 6-fold peak as compared with basal levels. After 240 minutes the levels remained significantly higher (P < 0.05) than the mean basal level at -30 and 0 minutes. No significant effects of clebopride were noted upon the circulating levels of LH and FSH. The peak PRL response to clebopride was unaffected by pretreatment with 100 mg of nomifensine, although the secretory area from 120 to 210 minutes after clebopride was greater (P < 0.05) in the nomifensine-treated group than in the control experiment. When 5 mg of bromocriptine were given before clebopride, the PRL response was completely abolished as compared with the control experiment (P < 0.001). Our data provide new evidence that dopaminergic receptors of the adeylate cyclase system are involved in the regulation of PRL secretion, acting at the pituitary level rather than acting on the hypothalamus. The PRL-releasing activity of clebopride could be the explanation for the occasional menstrual disorders and galactorrhea registered in some cases of long-term treatment.
D000328:Adult; D001549:Benzamides / Q000494:pharmacology*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008596:Menotropins / Q000097:blood; D009627:Nomifensine / Q000009:adverse effects / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D001549:Benzamides; D009627:Nomifensine; D001971:Bromocriptine; D008596:Menotropins; D011388:Prolactin; D007986:Luteinizing Hormone; C014417:clebopride